The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! The stock increased 4.51% or $0.31 during the last trading session, hitting $7.18. About 1.43M shares traded hands or 18.18% up from the average. Agenus Inc (NASDAQ:AGEN) has risen 140.21% since February 26, 2016 and is uptrending. It has outperformed by 129.79% the S&P500.
The move comes after 8 months positive chart setup for the $603.57 million company. It was reported on Oct, 1 by Barchart.com. We have $10.91 PT which if reached, will make NASDAQ:AGEN worth $313.86 million more.
Analysts await Agenus Inc (NASDAQ:AGEN) to report earnings on October, 25. They expect $-0.30 earnings per share, down 87.50% or $0.14 from last year’s $-0.16 per share. After $-0.24 actual earnings per share reported by Agenus Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Agenus Inc (NASDAQ:AGEN) Ratings Coverage
Out of 4 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Agenus has been the topic of 6 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Maxim Group upgraded Agenus Inc (NASDAQ:AGEN) on Friday, March 11 to “Buy” rating. On Monday, July 27 the stock rating was maintained by MLV with “Buy”. The firm has “Buy” rating by Jefferies given on Wednesday, December 16. The rating was downgraded by Maxim Group to “Hold” on Tuesday, October 27. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The stock of Agenus Inc (NASDAQ:AGEN) has “Buy” rating given on Friday, July 29 by Jefferies.
According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in Q2 2016. Its down 0.58, from 1.38 in 2016Q1. The ratio is negative, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Millennium Mngmt Ltd Liability Corporation, a New York-based fund reported 2.95 million shares. Susquehanna International Grp Llp owns 136,398 shares or 0% of their US portfolio. New York State Common Retirement Fund accumulated 0% or 69,600 shares. Blair William & Il accumulated 0% or 59,700 shares. Trellus Ltd Limited Liability Company holds 122,500 shares or 0.81% of its portfolio. Guggenheim Lc accumulated 0% or 20,164 shares. Oracle Inv Mgmt last reported 1.86 million shares in the company. The Pennsylvania-based Vanguard Group has invested 0% in Agenus Inc (NASDAQ:AGEN). The Pennsylvania-based Pnc Finance has invested 0% in Agenus Inc (NASDAQ:AGEN). Fisher Asset Mngmt Ltd Liability holds 93,132 shares or 0% of its portfolio. Blackrock Invest Lc last reported 288,041 shares in the company. Artal Group Incorporated reported 1.00 million shares or 0.08% of all its holdings. Geode Mngmt Ltd has 0% invested in the company for 511,363 shares. Rtw Lc holds 3.36% of its portfolio in Agenus Inc (NASDAQ:AGEN) for 2.43M shares. National Planning Corp has 0% invested in the company for 10,000 shares.
Insider Transactions: Since May 5, 2016, the stock had 3 buys, and 0 selling transactions for $513,570 net activity. Another trade for 100,000 shares valued at $317,895 was made by ARMEN GARO H on Thursday, May 5. $188,700 worth of Agenus Inc (NASDAQ:AGEN) was bought by WIINBERG ULF. Another trade for 2,250 shares valued at $6,975 was made by Baysal Ozer on Thursday, May 5.
AGEN Company Profile
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.